Compare Quest Diagnostics Inc (DGX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SYSCO Corporation — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays the higher dividend (2.81%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and SYSCO Corporation for 77 Days on average.
| DGX | SYY | |
|---|---|---|
Market Cap | $25.48B | $38.47B |
Volume | 941,866 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $247.45 | $91.16 |
52-Week Low | $173.49 | $69.30 |
Typical Hold Time | 56 Days | 77 Days |
Enterprise Value | $31.23B | $51.65B |
Dividend Yield | 1.49% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals and strong institutional support. The stock shows solid fundamentals with $81.37B revenue, 2.08% net margin, and attractive valuation at P/E 21.37 and P/S 0.44. Recent corporate actions include a $0.55 dividend and $1B stock offering, while the company reaffirmed fiscal 2027 guidance and launched a $500M AI efficiency program.
Sysco presents a balanced investment case with 60% analyst buy ratings and $85.75 consensus target offering 9.6% upside. The food distribution leader benefits from consistent revenue growth and AI-driven efficiency initiatives, though margin pressure and competitive threats warrant monitoring. Current valuation appears reasonable given the company's market position and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
